腹腔神经丛放射外科治疗晚期癌症疼痛管理:一项多中心、单臂、2期试验
这项多中心单臂2期试验在五国八家医院纳入125例胰腺癌或其他累及腹腔轴的肿瘤患者,给予腹腔神经丛单次25 Gy外照射光子放疗,90例可评估患者中48例(53%;95% CI 42-64)在3周时达到至少部分疼痛缓解,作者认为腹腔神经丛放射外科可能成为非侵入性姑息选择,但需随机对照研究进一步验证。
要点
- 90例可评估患者中48例(53%;95% CI 42-64)在治疗3周时达到至少部分疼痛缓解。
- 最常见的3-4级不良事件为腹痛(35/125,28%)和乏力(23/125,18%)。
- 作者认为腹腔神经丛放射外科可能成为腹膜后疼痛综合征的非侵入性姑息选择。
核心结论
- 腹腔神经丛放射外科可能成为腹膜后疼痛综合征患者的非侵入性姑息选择。
- 作者认为需要以传统腹腔神经丛阻滞或神经毁损术为对照进行随机比较以进一步研究。
研究设计与样本
- 多中心、单臂、2期研究,在五国(以色列、波兰、加拿大、美国、葡萄牙)八家医院开展。
- 纳入年龄18岁及以上、简明疼痛评估量表简表(BPI-SF)平均疼痛评分5-10分、东部肿瘤协作组体能状态评分0-2分、患胰腺癌或其他累及腹腔轴的肿瘤的患者。
- 干预为腹腔神经丛单次25 Gy外照射光子放疗。
- 主要终点为基于BPI-SF平均疼痛评分从基线至治疗后3周下降2分及以上的完全或部分疼痛缓解。
- 2018年1月3日至2021年12月28日共治疗125例患者,其中90例可评估,随访至死亡。
主要发现
- 可评估患者中位年龄65.5岁(IQR 58.3-71.8),50例(56%)为女性,40例(44%)为男性,83例(92%)患胰腺癌,77例(86%)为转移性疾病。
- 基线BPI-SF平均疼痛评分中位数为6分(IQR 5-7)。
- 90例可评估患者中,48例(53%;95% CI 42-64)在3周时达到至少部分疼痛缓解。
- 无论归因如何,最常见的3-4级不良事件为腹痛(35/125,28%)和乏力(23/125,18%)。
- 记录到11例3级或以上严重不良事件,其中2例3级严重不良事件被当地研究者判定为很可能与治疗相关(腹痛1例、恶心1例),9例被判定为可能与治疗相关(7例3级:血胆红素升高1例、十二指肠出血2例、腹痛2例、疾病进展2例;2例5级:治疗后24天疑似静脉曲张所致消化道出血1例、治疗后89天疾病进展(晚期胰腺癌)1例)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需要以传统腹腔神经丛阻滞或神经毁损术为对照进行随机比较以进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Refractory upper abdominal pain or lower back pain (retroperitoneal pain syndrome) related to celiac plexus involvement characterises pancreatic and other upper gastrointestinal malignancies and is an unmet need. We hypothesised that ablative radiation delivered to the celiac plexus would decrease pain. METHODS: This multicentre, single-arm, phase 2 study was done at eight hospitals in five countries (Israel, Poland, Canada, the USA, and Portugal). Eligible patients aged 18 years or older with an average pain level of 5-10 on the Brief Pain Inventory short form (BPI-SF), an Eastern Cooperative Oncology Group performance status score of 0-2, and either pancreatic cancer or other tumours involving the celiac axis, received a single fraction of 25 Gy of external-beam photons to the celiac plexus. The primary endpoint was complete or partial pain response based on a reduction of the BPI-SF average pain score of 2 points or more from baseline to 3 weeks after treatment. All evaluable patients with stable pain scores were included in response assessment. The trial is registered with ClinicalTrials.gov, NCT03323489, and is complete. FINDINGS: Between Jan 3, 2018, and Dec 28, 2021, 125 patients were treated, 90 of whom were evaluable. Patients were followed up until death. Median age was 65·5 years (IQR 58·3-71·8), 50 (56%) were female and 40 (44%) were male, 83 (92%) had pancreatic cancer, and 77 (86%) had metastatic disease. Median baseline BPI-SF average pain score was 6 (IQR 5-7). Of the 90 evaluable patients at 3 weeks, 48 (53%; 95% CI 42-64) had at least a partial pain response. The most common grade 3-4 adverse events, irrespective of attribution, were abdominal pain (35 [28%] of 125) and fatigue (23 [18%]). 11 serious adverse events of grade 3 or worse were recorded. Two grade 3 serious adverse events were probably attributed to treatment by the local investigators (abdominal pain [n=1] and nausea [n=1]), and nine were possibly attributed to treatment (seven were grade 3: blood bilirubin increased [n=1], duodenal haemorrhage [n=2], abdominal pain [n=2], and progressive disease [n=2]; and two were grade 5: gastrointestinal bleed from suspected varices 24 days after treatment [n=1] and progressive disease [advanced pancreatic cancer] 89 days after treatment [n=1]). INTERPRETATION: Celiac plexus radiosurgery could potentially be a non-invasive palliative option for patients with retroperitoneal pain syndrome. Further investigation by means of a randomised comparison with conventional celiac block or neurolysis is warranted. FUNDING: Gateway for Cancer Research and the Israel Cancer Association.
引用
- Lawrence YR, Miszczyk M, Dawson LA, et al. Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024. PMID: 39029483. doi:10.1016/S1470-2045(24)00223-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。